Jubilant DraxImage Inc. Receives CE Mark Certificate for Its Medical Device RUBY Rubidium Elution System™ (RbES) and Proprietary RUBY™ Consumable Accessories

Press Release (ePRNews.com) - MONTREAL - Jun 07, 2019 - ​Jubilant DraxImage Inc. (“DraxImage”), a wholly owned subsidiary of Jubilant Pharma Limited, is pleased to announce the receipt of the CE Mark certificate  for its state-of-the-art RUBY Rubidium Elution System (RbES) and the proprietary RUBY consumable accessories dedicated for use with their RUBY-FILL® (Rubidium Rb82 Generator). This certificate allows the device to be distributed into the European Economic Area (EEA).  

The RUBY-FILL® Generator and the RUBY Rubidium Elution System provide the latest technology in Positron Emission Tomography (PET) Myocardial Imaging. RUBY-FILL® is a closed system used to produce personalized patient doses of rubidium (Rb82) chloride injection for intravenous use. Rb82 chloride injection is a radioactive diagnostic agent indicated for PET imaging of the myocardium under rest or pharmacologic stress conditions to evaluate regional myocardial perfusion in adult patients with suspected or existing coronary artery disease.

Jubilant Pharma Senior Vice-President of Medical and Chief Medical Officer Dr. Norman LaFrance stated, “Jubilant DraxImage is extremely excited about the CE Mark certificate, which will provide expanded access of this next-generation PET product into the EEA. With its advanced weight-based dosing accuracy and infusion options, RUBY-FILL will enhance the way patients with known or suspected coronary artery disease are both diagnosed and managed.” 

“This approval is another landmark event for Jubilant DraxImage, supporting its ongoing commitment to the global expansion and utility of nuclear medicine and PET imaging. Our goal is to grow SPECT and PET imaging globally by providing products that enable physicians to deliver high-quality diagnostic studies as part of our mission of Improving Lives Through Nuclear Medicine,” stated Pramod Yadav, CEO Jubilant Pharma LTD.

For specific questions about the availability of RUBY-FILL® in your area, please email DraxImage Customer Service at customerservice@draximage.com.​

For more information, please contact:

James A. Kaufman, Vice President, Cardiovascular Business & Medical Device Development

Lisa F. Shearin, Director of Marketing, Cardiovascular


INDICATION (US): RUBY-FILL is a closed system used to produce rubidium (Rb82) chloride injection for intravenous use. Rubidium (Rb82) chloride injection is a radioactive diagnostic agent indicated for Positron Emission Tomography (PET) imaging of the myocardium under rest or pharmacologic stress conditions to evaluate regional myocardial perfusion in adult patients with suspected or existing coronary artery disease.

New Important Safety Information – April 2019 (US)


Please see full prescribing information for complete boxed warning.

High-Level Radiation Exposure with Use of Incorrect Eluent

Using the incorrect eluent can cause high Strontium (Sr 82) and (Sr 85) breakthrough levels (5.1)

• Use only additive-free 0.9% Sodium Chloride Injection USP to elute the generator (2.5)

• Immediately stop the patient infusion and discontinue the use of the affected RUBY-FILL generator if the incorrect solution is used to elute the generator (4)

• Evaluate the patient’s radiation absorbed dose and monitor for the effects of radiation to critical organs such as bone marrow (2.9)

Excess Radiation Exposure with Failure to Follow the Quality Control Testing Procedure

Excess radiation exposure occurs when the levels of Sr 82 or Sr 85 in the Rubidium Rb 82 Chloride injection exceed specific limits. (5.2)

• Strictly adhere to the generator quality control testing procedure. (2.6)

• Stop using the generator if it reaches any of its Expiration Limit. (2.7)

Please visit www.draximage.com for Full Prescribing Information. People are encouraged to report negative side effects of prescription drugs.

About Jubilant DraxImage

Jubilant DraxImage Inc., a subsidiary of Jubilant Life Sciences, develops, manufactures and commercializes radiopharmaceuticals used for the diagnosis and treatment of disease. The company is dedicated to nuclear medicine and serves customers and through them patients, globally, with high-quality and reliable products and services. The company is the market leader in North America for I-131 products (diagnosis and treatment of thyroid disorder and cancer), MAA (lung perfusion imaging), DTPA (renal, Brain imaging) and MDP (bone imaging), and also markets other products such as Sestamibi (myocardial perfusion imaging), Gluceptate (brain and renal imaging) and Rubidium-82 Generator (PET Cardiology). The company also has a strong development pipeline of new products. 

Source : Jubilant DraxImage Follow on Google News


Or using ePRNews Account

Don't have an account ? Sign Up

Register New Account

Already have an account ? Login

Reset Password

Already have an account ? Login


If you have any concerns regarding this press release, please contact the Author / Media Contact / Business of this press release. ePRNews is not resposible for the accuracy of the news posted and do not endorse, support any product/ services/ business mentioned and hereby disclaims any content contained in this press release.